A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer
Appl Clin Genet. 2021 May 20;14:255-266. doi: 10.2147/TACG.S261737. eCollection 2021.ABSTRACTBRCA2 is the most commonly implicated DNA damage repair gene associated with inherited prostate cancer. BRCA2 deficient prostate cancer typically presents at a younger age, is more poorly differentiated, and is associated with worse survival outcomes than non-BRCA2 associated prostate cancer. Despite these unfavourable prognostic implications, poly-ADP ribose polymerase inhibitors and platinum-based chemotherapy have been identified as potent targeted therapeutic agents towards BRCA1/2 deficient cancer cells. This review article ex...
Source: Clinical Prostate Cancer - July 23, 2021 Category: Cancer & Oncology Authors: Bradley King Jana McHugh Katie Snape Source Type: research

Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer
Jpn J Clin Oncol. 2021 Jul 23:hyab115. doi: 10.1093/jjco/hyab115. Online ahead of print.ABSTRACTBACKGROUND: Randomized trials showed the survival benefits of the combined use of androgen receptor axis-targeted agents with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer (mHSPC), regardless of the risk. However, treating patients with low-risk mHSPC with such intensive treatment is still debatable.METHODS: This retrospective study included 155 low-risk patients among 467 mHSPC patients treated in our affiliated institutions. The association between predictive factors and treatment outcomes was es...
Source: Clinical Prostate Cancer - July 23, 2021 Category: Cancer & Oncology Authors: Shunsuke Tsuzuki Shota Kawano Wataru Fukuokaya Keiichiro Mori Hideomi Nishikawa Kojiro Tashiro Daisuke Watanabe Taizo Uchimoto Kazuki Nishimura Yusuke Yano Masaya Murakami Yusuke Koike Kenichi Hata Haruhisa Koide Jun Miki Hirokazu Abe Hiroki Yamada Takehi Source Type: research

Postoperative radiotherapy after upfront radical prostatectomy: debated issues at a turning point-a survey exploring management trends on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology)
CONCLUSIONS: Overall, good level of agreement was found between participants for most of the topics. Most debated issues regarded, as expected, implementation of new imaging methods in this setting. Notably, trend in favour of early SRT vs. immediate adjuvant RT was underlined, and preference for global evaluation rather than isolated risk factors for RT indications was noticed.PMID:34286475 | DOI:10.1007/s12094-021-02665-y (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 21, 2021 Category: Cancer & Oncology Authors: G Francolini G Timon F Matrone G Marvaso L Nicosia L Ognibene A Vinciguerra L E Trodella C Franzese P Borghetti B A Jereczek-Fossa S Arcangeli Source Type: research

Need of support perceived by patients primarily curatively treated for breast, colorectal, or prostate cancer and close to discharge from hospital-A qualitative study
CONCLUSION: To empower patients who are ending primary treatment and being close to discharge from hospital, healthcare professionals should recognise patients' shifting needs and adapt the support. Adapted support is significant for patients' sense of safety. Biomedical information is not sufficient to fully support patients.RELEVANCE TO CLINICAL PRACTICE: Offering easy access to supportive care when primary treatment is finished could diminish people's stress, insecurity and avoidable use of healthcare services. Even after discharge, nurses preferably should adapt and offer support tailored to patients' needs. Such suppo...
Source: Clinical Prostate Cancer - July 21, 2021 Category: Cancer & Oncology Authors: Senada Hajdarevic Ulrika Fallbj örk Per Fransson Sture Åström Source Type: research

Postoperative radiotherapy after upfront radical prostatectomy: debated issues at a turning point-a survey exploring management trends on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology)
CONCLUSIONS: Overall, good level of agreement was found between participants for most of the topics. Most debated issues regarded, as expected, implementation of new imaging methods in this setting. Notably, trend in favour of early SRT vs. immediate adjuvant RT was underlined, and preference for global evaluation rather than isolated risk factors for RT indications was noticed.PMID:34286475 | DOI:10.1007/s12094-021-02665-y (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 21, 2021 Category: Cancer & Oncology Authors: G Francolini G Timon F Matrone G Marvaso L Nicosia L Ognibene A Vinciguerra L E Trodella C Franzese P Borghetti B A Jereczek-Fossa S Arcangeli Source Type: research

Need of support perceived by patients primarily curatively treated for breast, colorectal, or prostate cancer and close to discharge from hospital-A qualitative study
CONCLUSION: To empower patients who are ending primary treatment and being close to discharge from hospital, healthcare professionals should recognise patients' shifting needs and adapt the support. Adapted support is significant for patients' sense of safety. Biomedical information is not sufficient to fully support patients.RELEVANCE TO CLINICAL PRACTICE: Offering easy access to supportive care when primary treatment is finished could diminish people's stress, insecurity and avoidable use of healthcare services. Even after discharge, nurses preferably should adapt and offer support tailored to patients' needs. Such suppo...
Source: Clinical Prostate Cancer - July 21, 2021 Category: Cancer & Oncology Authors: Senada Hajdarevic Ulrika Fallbj örk Per Fransson Sture Åström Source Type: research

A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kbeta inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
CONCLUSIONS: Although there was acceptable safety and tolerability with GSK2636771 plus enzalutamide in patients with PTEN-deficient mCRPC after failing enzalutamide, limited antitumor activity was observed.PMID:34281912 | DOI:10.1158/1078-0432.CCR-21-1115 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 20, 2021 Category: Cancer & Oncology Authors: Debashis Sarker Nancy A Dawson Ana M Aparicio Tanya B Dorff Allan J Pantuck Ulka N Vaishampayan Lynn Henson Lakshmi Vasist Sumita Roy-Ghanta Michele Gorczyca Whitney York Gopinath Ganji Jerry Tolson Johann S de Bono Source Type: research

Statins for prostate cancer: when and how much?
Clin Cancer Res. 2021 Jul 19:clincanres.1891.2021. doi: 10.1158/1078-0432.CCR-21-1891. Online ahead of print.ABSTRACTStatins have plausible biological effects against prostate cancer cells and are associated with improved disease-specific mortality. In current randomized placebo-controlled trial low-dose atorvastatin caused no difference in relapses after radical prostatectomy in Asian men. Future trials should study higher statin doses at later disease stages with survival as the endpoint.PMID:34281913 | DOI:10.1158/1078-0432.CCR-21-1891 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 20, 2021 Category: Cancer & Oncology Authors: Teemu J Murtola Aino Siltari Source Type: research

68Ga-PSMA Uptake Patterns of Clear Cell Renal Carcinoma Across Different Histopathological Subtypes
Clin Nucl Med. 2021 Jul 20. doi: 10.1097/RLU.0000000000003814. Online ahead of print.ABSTRACT68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a well-established imaging modality in patients with prostate cancer; however, PSMA expression is also reported in the tumor-associated neovasculature, including but not limited to hepatocellular carcinoma, breast cancer, and renal cell carcinoma. Herein, we present 2 patients diagnosed with different histopathological subtypes of renal cell carcinoma who underwent 68Ga-PSMA PET/CT before surgery. Both cases have different PSMA expression characteristics and are presented alo...
Source: Clinical Prostate Cancer - July 20, 2021 Category: Cancer & Oncology Authors: Melis Oflas Yasemin Ozluk Oner Sanli Zeynep Gozde Ozkan Serkan Kuyumcu Source Type: research

A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kbeta inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
CONCLUSIONS: Although there was acceptable safety and tolerability with GSK2636771 plus enzalutamide in patients with PTEN-deficient mCRPC after failing enzalutamide, limited antitumor activity was observed.PMID:34281912 | DOI:10.1158/1078-0432.CCR-21-1115 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 20, 2021 Category: Cancer & Oncology Authors: Debashis Sarker Nancy A Dawson Ana M Aparicio Tanya B Dorff Allan J Pantuck Ulka N Vaishampayan Lynn Henson Lakshmi Vasist Sumita Roy-Ghanta Michele Gorczyca Whitney York Gopinath Ganji Jerry Tolson Johann S de Bono Source Type: research

Statins for prostate cancer: when and how much?
Clin Cancer Res. 2021 Jul 19:clincanres.1891.2021. doi: 10.1158/1078-0432.CCR-21-1891. Online ahead of print.ABSTRACTStatins have plausible biological effects against prostate cancer cells and are associated with improved disease-specific mortality. In current randomized placebo-controlled trial low-dose atorvastatin caused no difference in relapses after radical prostatectomy in Asian men. Future trials should study higher statin doses at later disease stages with survival as the endpoint.PMID:34281913 | DOI:10.1158/1078-0432.CCR-21-1891 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 20, 2021 Category: Cancer & Oncology Authors: Teemu J Murtola Aino Siltari Source Type: research

A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome
Clin Med Insights Oncol. 2021 Jul 2;15:11795549211028569. doi: 10.1177/11795549211028569. eCollection 2021.ABSTRACTPathogenic germline mutations occurring in the BRCA1 (MIM:113705) and BRCA2 (MIM: 600185), which always result in truncated protein or nonsense-mediated mRNA decay, have been identified to increase the risk of hereditary breast, ovarian, pancreatic, prostate, and melanoma cancers. Recent studies show that BRCA1/2 germline mutations also contribute to half of all hereditary breast and ovarian cancer (HBOC). In this case series, we reported a novel frameshift mutation of the BRCA1 gene. This novel frameshift mut...
Source: Clinical Prostate Cancer - July 19, 2021 Category: Cancer & Oncology Authors: Yanmei Wu Xiaodong Pan Juan Dou Quan Zhang Yuantong Li Yuan Sheng Xishui Liu Source Type: research

Prevalence of serum galectin-1 autoantibodies in seven types of cancer: A potential biomarker
Mol Clin Oncol. 2021 Sep;15(3):179. doi: 10.3892/mco.2021.2341. Epub 2021 Jul 1.ABSTRACTAlthough serum galectin-1 antibodies (s-GAL-1-Abs) have been evaluated in a small number of patients with cancer, a large series of patients with different cancer types have not been reported. The current study evaluated 1,833 patients with esophageal cancer (n=172), gastric cancer (n=317), colorectal cancer (n=262), hepatocellular carcinoma (n=91), prostate cancer (n=358), breast cancer (n=364), lung cancer (n=269) and 72 healthy individuals. s-GAL-1-Abs levels were analyzed using an originally developed ELISA system. A cut-off optical...
Source: Clinical Prostate Cancer - July 19, 2021 Category: Cancer & Oncology Authors: Tatsuki Nanami Isamu Hoshino Fumiaki Shiratori Satoshi Yajima Yoko Oshima Takashi Suzuki Masaaki Ito Takaki Hiwasa Akiko Kuwajima Hideaki Shimada Source Type: research

The influence of testosterone suppression on HER2 immunoexpression in prostatic neoplastic tissue
Mol Clin Oncol. 2021 Sep;15(3):185. doi: 10.3892/mco.2021.2347. Epub 2021 Jul 8.ABSTRACTDuring initial risk assessments, the metastatic potential of prostate cancer (PCa) may not be fully considered. The tumor's multicentric origin, which is associated with genetic mutations, may explain existing treatment limitations. Investigating human epidermal growth factor receptor 2 (HER2) expression in patients with different stages of PCa may therefore increase understanding of the mechanisms associated with the development of castration resistance. The present study examined the association between HER2 expression and the histolo...
Source: Clinical Prostate Cancer - July 19, 2021 Category: Cancer & Oncology Authors: Guilherme Andrade Peixoto Fernando Korkes Cristiano Linck Pazeto Marilia Germanos De Castro Thiago Fernandes Negris Lima Marcelo Langer Wroclawski Nicolle Martin Christofe Marcos Tobias-Machado Lucila Heloisa Simardi Santiago Sidney Glina Source Type: research

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer
CONCLUSIONS: With PSMA-11-PET we are able to select patients with oligometastatic recurrent prostate cancer suitable for SABR in an earlier disease stage at lower PSA levels. PSMA-11-PET guided SABR resulted in a significant longer response duration and ADT-free survival compared with choline-PET and can therefore prevent or delay ADT related side effects.PMID:34278008 | PMC:PMC8261473 | DOI:10.1016/j.ctro.2021.06.004 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 19, 2021 Category: Cancer & Oncology Authors: Charlotte L Deijen Gerbert L Vrijenhoek Eva E Schaake Wouter V Vogel Luc M F Moonen Floris J Pos Henk G van der Poel Gerben R Borst Source Type: research

Development and internal validation of multivariable prediction models for biochemical failure after MRI-guided focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer
CONCLUSION: Two models are provided for prediction of BF in patients with radiorecurrent PCa treated with FS-HDR-BT. Based on pre- and post-salvage characteristics, we are able to identify patients with a high risk of BF. These findings can aid patient counselling for FS-HDR-BT.PMID:34278009 | PMC:PMC8261471 | DOI:10.1016/j.ctro.2021.06.005 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 19, 2021 Category: Cancer & Oncology Authors: Thomas Willigenburg Marieke J van Son Sandrine M G van de Pol Wietse S C Eppinga Jan J W Lagendijk Hans C J de Boer Marinus A Moerland Jochem R N van der Voort van Zyp Max Peters Source Type: research

Independent Predicting Factors for Subcutaneous Emphysema Associated with Robotic-Assisted Laparoscopic Radical Prostatectomy: A Retrospective Single-Center Study
J Clin Med. 2021 Jul 4;10(13):2985. doi: 10.3390/jcm10132985.ABSTRACTOBJECTIVES: Subcutaneous emphysema (SCE) is a complication associated with laparoscopic surgery. Severe SCE complicated by excessive hypercarbia may afford detrimental effects in surgical patients with cardiac dysfunction. Robotic-assisted laparoscopic radical prostatectomy (RALP) has several predisposing factors that contribute to SCE. The main purpose of our single-center retrospective study was to determine the preoperative and intraoperative predicting factors for SCE associated with RALP and to determine the actual incidence of SCE.METHODS: In total,...
Source: Clinical Prostate Cancer - July 19, 2021 Category: Cancer & Oncology Authors: Waichi Yamamoto Tasuku Nishihara Taisuke Hamada Mikiko Takeuchi Hideyuki Nandate Sakiko Kitamura Yasushi Takasaki Toshihiro Yorozuya Source Type: research

A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome
Clin Med Insights Oncol. 2021 Jul 2;15:11795549211028569. doi: 10.1177/11795549211028569. eCollection 2021.ABSTRACTPathogenic germline mutations occurring in the BRCA1 (MIM:113705) and BRCA2 (MIM: 600185), which always result in truncated protein or nonsense-mediated mRNA decay, have been identified to increase the risk of hereditary breast, ovarian, pancreatic, prostate, and melanoma cancers. Recent studies show that BRCA1/2 germline mutations also contribute to half of all hereditary breast and ovarian cancer (HBOC). In this case series, we reported a novel frameshift mutation of the BRCA1 gene. This novel frameshift mut...
Source: Clinical Prostate Cancer - July 19, 2021 Category: Cancer & Oncology Authors: Yanmei Wu Xiaodong Pan Juan Dou Quan Zhang Yuantong Li Yuan Sheng Xishui Liu Source Type: research

Prevalence of serum galectin-1 autoantibodies in seven types of cancer: A potential biomarker
Mol Clin Oncol. 2021 Sep;15(3):179. doi: 10.3892/mco.2021.2341. Epub 2021 Jul 1.ABSTRACTAlthough serum galectin-1 antibodies (s-GAL-1-Abs) have been evaluated in a small number of patients with cancer, a large series of patients with different cancer types have not been reported. The current study evaluated 1,833 patients with esophageal cancer (n=172), gastric cancer (n=317), colorectal cancer (n=262), hepatocellular carcinoma (n=91), prostate cancer (n=358), breast cancer (n=364), lung cancer (n=269) and 72 healthy individuals. s-GAL-1-Abs levels were analyzed using an originally developed ELISA system. A cut-off optical...
Source: Clinical Prostate Cancer - July 19, 2021 Category: Cancer & Oncology Authors: Tatsuki Nanami Isamu Hoshino Fumiaki Shiratori Satoshi Yajima Yoko Oshima Takashi Suzuki Masaaki Ito Takaki Hiwasa Akiko Kuwajima Hideaki Shimada Source Type: research

The influence of testosterone suppression on HER2 immunoexpression in prostatic neoplastic tissue
Mol Clin Oncol. 2021 Sep;15(3):185. doi: 10.3892/mco.2021.2347. Epub 2021 Jul 8.ABSTRACTDuring initial risk assessments, the metastatic potential of prostate cancer (PCa) may not be fully considered. The tumor's multicentric origin, which is associated with genetic mutations, may explain existing treatment limitations. Investigating human epidermal growth factor receptor 2 (HER2) expression in patients with different stages of PCa may therefore increase understanding of the mechanisms associated with the development of castration resistance. The present study examined the association between HER2 expression and the histolo...
Source: Clinical Prostate Cancer - July 19, 2021 Category: Cancer & Oncology Authors: Guilherme Andrade Peixoto Fernando Korkes Cristiano Linck Pazeto Marilia Germanos De Castro Thiago Fernandes Negris Lima Marcelo Langer Wroclawski Nicolle Martin Christofe Marcos Tobias-Machado Lucila Heloisa Simardi Santiago Sidney Glina Source Type: research

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer
CONCLUSIONS: With PSMA-11-PET we are able to select patients with oligometastatic recurrent prostate cancer suitable for SABR in an earlier disease stage at lower PSA levels. PSMA-11-PET guided SABR resulted in a significant longer response duration and ADT-free survival compared with choline-PET and can therefore prevent or delay ADT related side effects.PMID:34278008 | PMC:PMC8261473 | DOI:10.1016/j.ctro.2021.06.004 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 19, 2021 Category: Cancer & Oncology Authors: Charlotte L Deijen Gerbert L Vrijenhoek Eva E Schaake Wouter V Vogel Luc M F Moonen Floris J Pos Henk G van der Poel Gerben R Borst Source Type: research

Development and internal validation of multivariable prediction models for biochemical failure after MRI-guided focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer
CONCLUSION: Two models are provided for prediction of BF in patients with radiorecurrent PCa treated with FS-HDR-BT. Based on pre- and post-salvage characteristics, we are able to identify patients with a high risk of BF. These findings can aid patient counselling for FS-HDR-BT.PMID:34278009 | PMC:PMC8261471 | DOI:10.1016/j.ctro.2021.06.005 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 19, 2021 Category: Cancer & Oncology Authors: Thomas Willigenburg Marieke J van Son Sandrine M G van de Pol Wietse S C Eppinga Jan J W Lagendijk Hans C J de Boer Marinus A Moerland Jochem R N van der Voort van Zyp Max Peters Source Type: research

RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma
This study provides new insights into the mechanisms driving HCC tumorigenesis and new therapeutic targets.PMID:34275027 | DOI:10.1007/s10238-021-00742-8 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 18, 2021 Category: Cancer & Oncology Authors: Yue Li Xiaoqin He Xiaoyu Zhang Yangtao Xu Wenliang Chen Xin Liu Ximing Xu Source Type: research

Population pharmacokinetics of ipatasertib and its metabolite in cancer patients
This study was undertaken to characterize pharmacokinetics profiles of ipatasertib and its metabolite M1 (G-037720), and to understand the sources of variability. Population pharmacokinetic models of ipatasertib and M1 were developed separately using data from 342 individuals with cancer from five Phase I and II studies. The final population pharmacokinetic models for ipatasertib and M1 were three-compartmental, with first-order elimination and sequential zero- and first-order absorption. Ipatasertib bioavailability and M1 formation increased after multiple dosing resulting in an increase in exposure beyond that expected f...
Source: Clinical Prostate Cancer - July 17, 2021 Category: Cancer & Oncology Authors: Kenta Yoshida Justin Wilkins Julia Winkler Janet R Wade Naoki Kotani Nina Wang Rucha Sane Pascal Chanu Source Type: research

Population pharmacokinetics of ipatasertib and its metabolite in cancer patients
This study was undertaken to characterize pharmacokinetics profiles of ipatasertib and its metabolite M1 (G-037720), and to understand the sources of variability. Population pharmacokinetic models of ipatasertib and M1 were developed separately using data from 342 individuals with cancer from five Phase I and II studies. The final population pharmacokinetic models for ipatasertib and M1 were three-compartmental, with first-order elimination and sequential zero- and first-order absorption. Ipatasertib bioavailability and M1 formation increased after multiple dosing resulting in an increase in exposure beyond that expected f...
Source: Clinical Prostate Cancer - July 17, 2021 Category: Cancer & Oncology Authors: Kenta Yoshida Justin Wilkins Julia Winkler Janet R Wade Naoki Kotani Nina Wang Rucha Sane Pascal Chanu Source Type: research

Ductal Variant of Prostate Cancer: Serial Imaging With 18F-PSMA PET/CT
Clin Nucl Med. 2021 Jul 14. doi: 10.1097/RLU.0000000000003799. Online ahead of print.ABSTRACTA 51-year-old man with high-grade ductal variant of prostate cancer with normal prostate-specific antigen (PSA) levels underwent radical prostatectomy. Follow-up 18F-prostate-specific membrane antigen-targeted ligand 1007 (PSMA-1007) PET/CT revealed enlarged PSMA-expressing left common iliac node. Patient was placed on androgen deprivation therapy and was lost to follow-up. Repeat 18F-PSMA PET/CT scan after 16 months showed disease progression. PSA levels were still within normal limits. This case highlights the utility of 18F-PSMA...
Source: Clinical Prostate Cancer - July 16, 2021 Category: Cancer & Oncology Authors: Yazan Z Alabed Source Type: research

Targeting the spectrum of immune checkpoints in prostate cancer
Expert Rev Clin Pharmacol. 2021 Jul 15:1-14. doi: 10.1080/17512433.2021.1949287. Online ahead of print.ABSTRACTIntroduction: The proven efficacy of the cellular vaccine sipuleucel-T in 2010 led to optimism about immunotherapeutic approaches for the treatment of prostate cancer. Some surmised that prostate cancer might be an ideal target for immune-mediated killing given that the prostate is not an essential organ and expresses unique proteins including prostate-specific antigen, prostate-specific membrane antigen, and prostatic acid phosphatase that could be targeted without side effects. Subsequently, antibodies that inhi...
Source: Clinical Prostate Cancer - July 15, 2021 Category: Cancer & Oncology Authors: Laura A Sena Samuel R Denmeade Emmanuel S Antonarakis Source Type: research

Targeting the spectrum of immune checkpoints in prostate cancer
Expert Rev Clin Pharmacol. 2021 Jul 15:1-14. doi: 10.1080/17512433.2021.1949287. Online ahead of print.ABSTRACTIntroduction: The proven efficacy of the cellular vaccine sipuleucel-T in 2010 led to optimism about immunotherapeutic approaches for the treatment of prostate cancer. Some surmised that prostate cancer might be an ideal target for immune-mediated killing given that the prostate is not an essential organ and expresses unique proteins including prostate-specific antigen, prostate-specific membrane antigen, and prostatic acid phosphatase that could be targeted without side effects. Subsequently, antibodies that inhi...
Source: Clinical Prostate Cancer - July 15, 2021 Category: Cancer & Oncology Authors: Laura A Sena Samuel R Denmeade Emmanuel S Antonarakis Source Type: research

FOXA1 promotes prostate cancer angiogenesis by inducing multiple pro-angiogenic factors expression
CONCLUSION: Overall, these findings illustrated a tumor angiogenesis-promoting role of FOXA1 in prostate cancer.PMID:34258652 | DOI:10.1007/s00432-021-03730-3 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 14, 2021 Category: Cancer & Oncology Authors: Yiming Su Yu Zhang Jing Zhao Wenhao Zhou Wenhao Wang Bangmin Han Xiaohai Wang Source Type: research

FOXA1 promotes prostate cancer angiogenesis by inducing multiple pro-angiogenic factors expression
CONCLUSION: Overall, these findings illustrated a tumor angiogenesis-promoting role of FOXA1 in prostate cancer.PMID:34258652 | DOI:10.1007/s00432-021-03730-3 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 14, 2021 Category: Cancer & Oncology Authors: Yiming Su Yu Zhang Jing Zhao Wenhao Zhou Wenhao Wang Bangmin Han Xiaohai Wang Source Type: research

Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents
CONCLUSIONS: The introduction of cabazitaxel as a third-line agent could markedly improve the prognostic outcomes of mCRPC patients.PMID:34255227 | DOI:10.1007/s10147-021-01956-2 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 13, 2021 Category: Cancer & Oncology Authors: Hideaki Miyake Ryo Sato Kyohei Watanabe Yuto Matsushita Hiromitsu Watanabe Daisuke Motoyama Toshiki Ito Takayuki Sugiyama Atsushi Otsuka Source Type: research

In1-ghrelin splicing variant as a key element in the pathophysiological association between obesity and prostate cancer
CONCLUSIONS: Urine In1-ghrelin levels are associated with obesity-related factors and PCa risk/aggressiveness, and could represent a novel and valuable non-invasive PCa biomarker, as well as a potential link in the pathophysiological relationship between obesity and PCa.PMID:34255835 | DOI:10.1210/clinem/dgab516 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 13, 2021 Category: Cancer & Oncology Authors: Juan M Jim énez-Vacas Antonio J Montero-Hidalgo Enrique G ómez-Gómez Antonio C Fuentes-Fayos Francisco Ruiz-Pino Ipek Guler Antonio Camargo Francisco J Anglada Julia Carrasco-Valiente Manuel Tena-Sempere Andr é Sarmento-Cabral Justo P Casta ño Manuel Source Type: research

Determination of camostat and its metabolites in human plasma - preservation of samples and quantification by a validated UHPLC-MS/MS method
CONCLUSIONS: A methodology was developed that preserves camostat and GBPA in plasma samples and provides accurate and sensitive quantification of camostat, GBPA and GBA by UHPLC-MS/MS.PMID:34252447 | DOI:10.1016/j.clinbiochem.2021.07.007 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 12, 2021 Category: Cancer & Oncology Authors: Lambert K S ørensen J ørgen B Hasselstrøm Jesper D Gunst Ole S S øgaard Mads Kjolby Source Type: research

Determination of camostat and its metabolites in human plasma - preservation of samples and quantification by a validated UHPLC-MS/MS method
CONCLUSIONS: A methodology was developed that preserves camostat and GBPA in plasma samples and provides accurate and sensitive quantification of camostat, GBPA and GBA by UHPLC-MS/MS.PMID:34252447 | DOI:10.1016/j.clinbiochem.2021.07.007 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 12, 2021 Category: Cancer & Oncology Authors: Lambert K S ørensen J ørgen B Hasselstrøm Jesper D Gunst Ole S S øgaard Mads Kjolby Source Type: research

Can high b-value 3.0 T biparametric MRI with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naive men?
CONCLUSION: There was no significant difference in the detection efficacy of high b-value bp-MRI based on the S-PI-RADS score for prostate cancer and clinically significant prostate cancer compared with the standard PI-RADS v2 score with mp-MRI protocols, which can be applied clinically.PMID:34243992 | DOI:10.1016/j.clinimag.2021.06.024 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 10, 2021 Category: Cancer & Oncology Authors: Gang Wang Gang Yu Jing Chen Guang Yang Haixia Xu Zegu Chen Guoren Wang Zhiming Bai Source Type: research

Can high b-value 3.0 T biparametric MRI with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naive men?
CONCLUSION: There was no significant difference in the detection efficacy of high b-value bp-MRI based on the S-PI-RADS score for prostate cancer and clinically significant prostate cancer compared with the standard PI-RADS v2 score with mp-MRI protocols, which can be applied clinically.PMID:34243992 | DOI:10.1016/j.clinimag.2021.06.024 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 10, 2021 Category: Cancer & Oncology Authors: Gang Wang Gang Yu Jing Chen Guang Yang Haixia Xu Zegu Chen Guoren Wang Zhiming Bai Source Type: research

Can high b-value 3.0 T biparametric MRI with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naive men?
CONCLUSION: There was no significant difference in the detection efficacy of high b-value bp-MRI based on the S-PI-RADS score for prostate cancer and clinically significant prostate cancer compared with the standard PI-RADS v2 score with mp-MRI protocols, which can be applied clinically.PMID:34243992 | DOI:10.1016/j.clinimag.2021.06.024 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 10, 2021 Category: Cancer & Oncology Authors: Gang Wang Gang Yu Jing Chen Guang Yang Haixia Xu Zegu Chen Guoren Wang Zhiming Bai Source Type: research

Detection of Diffuse Peritoneal and Omental Metastases From Prostate Cancer With 18F-PSMA-1007 PET/CT
We report a case of an 80-year-old man who was suspected of prostate carcinoma metastasis and underwent 18F-PSMA-1007 PET/CT for restaging the disease. PET/CT imaging presented intense tracer uptake in the prostate gland, multiple lymph nodes, and bones. Interestingly, we found extremely increased radioactive uptake of diffuse peritoneum and omentum on 18F-PSMA-1007 PET/CT images, which are very rare metastatic sites for prostate cancer.PMID:34238806 | DOI:10.1097/RLU.0000000000003802 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 9, 2021 Category: Cancer & Oncology Authors: Xiaowei Ji Ling Wang Jie Lin Kun Tang Source Type: research

Association of Vitamin K and Non-Vitamin K Oral Anticogulant Use And Cancer Incidence In Atrial Fibrillation Patients
Clin Pharmacol Ther. 2021 Jul 9. doi: 10.1002/cpt.2362. Online ahead of print.ABSTRACTThe association between the use of Vitamin K antagonists (VKA) and cancer risk reduction remains unclear. We aimed to assess the association between the use of VKA or DOAC and the incidence of cancer in a large cohort of AF patients by meaans of a population-based, propensity-weighted cohort study using population-wide databases including patients diagnosed with non-valvular AF (NVAF) followed for up of 5 years (median 2.94 years). We created two cohorts based on the initiation therapy (VKA or DOAC). Initiation with VKA or DOAC was define...
Source: Clinical Prostate Cancer - July 9, 2021 Category: Cancer & Oncology Authors: Adina A Iftimi Clara L Rodr íguez-Bernal Salvador Peir ó Santiago Bonanad Andreu Ferrero-Gregori Isabel Hurtado An íbal García-Sempere Gabriel Sanf élix-Gimeno Source Type: research

Emerging role for local therapy in oligometastatic prostate cancer
Clin Adv Hematol Oncol. 2021 Jul;19(7):460-467.ABSTRACTOligometastatic prostate cancer is a subtype of metastatic disease that generally is defined by the presence of 5 or fewer metastatic lesions. Metastatic prostate cancer currently is treated with androgen deprivation therapy and additional systemic therapy, such as novel antiandrogen medications or chemotherapy. The management of metastatic prostate cancer is evolving, however, with the notion that some patients with low-burden metastatic disease may benefit from both local and systemic therapy. Local therapy of the prostate in the setting of oligometastatic prostate c...
Source: Clinical Prostate Cancer - July 8, 2021 Category: Cancer & Oncology Authors: Nabila R Khondakar Jeunice Owens-Walton Michael Daneshvar Cheyenne Williams Luke O'Connor Nitin K Yerram Peter A Pinto Source Type: research

Emerging role for local therapy in oligometastatic prostate cancer
Clin Adv Hematol Oncol. 2021 Jul;19(7):460-467.ABSTRACTOligometastatic prostate cancer is a subtype of metastatic disease that generally is defined by the presence of 5 or fewer metastatic lesions. Metastatic prostate cancer currently is treated with androgen deprivation therapy and additional systemic therapy, such as novel antiandrogen medications or chemotherapy. The management of metastatic prostate cancer is evolving, however, with the notion that some patients with low-burden metastatic disease may benefit from both local and systemic therapy. Local therapy of the prostate in the setting of oligometastatic prostate c...
Source: Clinical Prostate Cancer - July 8, 2021 Category: Cancer & Oncology Authors: Nabila R Khondakar Jeunice Owens-Walton Michael Daneshvar Cheyenne Williams Luke O'Connor Nitin K Yerram Peter A Pinto Source Type: research

Impact of prostate focused alignment on planned pelvic lymph node dose
CONCLUSIONS: The results indicate a significant difference exists between the planned coverage and calculated delivered coverage for the LN PTV. There was no significant difference found for the LN CTV. We conclude that lymph node motion must be considered with the prostate motion when aligning patients before each fraction.PMID:34231945 | DOI:10.1002/acm2.13092 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 7, 2021 Category: Cancer & Oncology Authors: Joshua Kilian-Meneghin Tianjun Ma Lalith Kumaraswamy Source Type: research

Impact of prostate focused alignment on planned pelvic lymph node dose
CONCLUSIONS: The results indicate a significant difference exists between the planned coverage and calculated delivered coverage for the LN PTV. There was no significant difference found for the LN CTV. We conclude that lymph node motion must be considered with the prostate motion when aligning patients before each fraction.PMID:34231945 | DOI:10.1002/acm2.13092 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 7, 2021 Category: Cancer & Oncology Authors: Joshua Kilian-Meneghin Tianjun Ma Lalith Kumaraswamy Source Type: research

Current Opinion Regarding Multidisciplinary Cancer Clinic Utilization for the Management of Prostate Cancer
CONCLUSION: A contemporary sampling of urologists' opinion and practice patterns alludes to the benefits that advocate for and the resource demand that hinders routine use of MDC for PCa evaluation. Urologist training and practice environment can affect participation in PCa MDC.PMID:34221638 | PMC:PMC8248076 | DOI:10.25259/JCIS_73_2021 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Daniel J Lama Matthew Kasson Connor Hoge Tian Guan Marepalli Rao Timothy Struve Sadhna Verma Abhinav Sidana Source Type: research

Bladder neck sparing during robot-assisted laparoscopic radical prostatectomy: Six-year experience
CONCLUSION: Since we have defined bladder neck sparing technique, we have realized that our technique is very effective with our long-term results. Our novel technique provided very early continence at the time of catheter removal after RALP within short-term follow-up in addition to favorable oncologic results.PMID:34222808 | PMC:PMC8240237 | DOI:10.14744/nci.2020.49092 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Sercan Yilmaz Esat Ak Eymen Gazel Serdar Yalcin Kenan Yigit Yildiz Lutfi Tunc Source Type: research

Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients
CONCLUSION: Our study provides knowledge on abiraterone and enzalutamide real-life safety profiles, especially for events leading to hospitalisation. Despite several limitations, including the lack of clinical data, the safety signal for AKI under abiraterone is in line with results of an analysis of the French pharmacovigilance database, which requires further specific investigations. Enlightening the clinicians' therapeutic choices for patients treated for prostate cancer, our study should lead to clinicians to be cautious in the use of abiraterone.PMID:34224605 | DOI:10.1111/bcp.14972 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Lucie-Marie Scailteux Fabien Despas Fr édéric Balusson Boris Campillo-Gimenez Romain Mathieu S ébastien Vincendeau Andr é Happe Emmanuel Nowak Sandrine Kerbrat Emmanuel Oger Source Type: research

Current Opinion Regarding Multidisciplinary Cancer Clinic Utilization for the Management of Prostate Cancer
CONCLUSION: A contemporary sampling of urologists' opinion and practice patterns alludes to the benefits that advocate for and the resource demand that hinders routine use of MDC for PCa evaluation. Urologist training and practice environment can affect participation in PCa MDC.PMID:34221638 | PMC:PMC8248076 | DOI:10.25259/JCIS_73_2021 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Daniel J Lama Matthew Kasson Connor Hoge Tian Guan Marepalli Rao Timothy Struve Sadhna Verma Abhinav Sidana Source Type: research

Bladder neck sparing during robot-assisted laparoscopic radical prostatectomy: Six-year experience
CONCLUSION: Since we have defined bladder neck sparing technique, we have realized that our technique is very effective with our long-term results. Our novel technique provided very early continence at the time of catheter removal after RALP within short-term follow-up in addition to favorable oncologic results.PMID:34222808 | PMC:PMC8240237 | DOI:10.14744/nci.2020.49092 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Sercan Yilmaz Esat Ak Eymen Gazel Serdar Yalcin Kenan Yigit Yildiz Lutfi Tunc Source Type: research

Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients
CONCLUSION: Our study provides knowledge on abiraterone and enzalutamide real-life safety profiles, especially for events leading to hospitalisation. Despite several limitations, including the lack of clinical data, the safety signal for AKI under abiraterone is in line with results of an analysis of the French pharmacovigilance database, which requires further specific investigations. Enlightening the clinicians' therapeutic choices for patients treated for prostate cancer, our study should lead to clinicians to be cautious in the use of abiraterone.PMID:34224605 | DOI:10.1111/bcp.14972 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Lucie-Marie Scailteux Fabien Despas Fr édéric Balusson Boris Campillo-Gimenez Romain Mathieu S ébastien Vincendeau Andr é Happe Emmanuel Nowak Sandrine Kerbrat Emmanuel Oger Source Type: research

Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications
Clin Chim Acta. 2021 Jul 1:S0009-8981(21)00231-X. doi: 10.1016/j.cca.2021.06.030. Online ahead of print.ABSTRACTBACKGROUND: A sensitive liquid chromatography tandem-mass spectrometry (LC-MS/MS) method was used to monitor serum testosterone levels in castrated prostate cancer patients. We subsequently performed an observational and retrospective study to estimate the within- and between-subject biological variation of these patients.METHODS: In total, 474 samples from 72 prostate cancer patients in the Netherlands receiving either chemical castration (CAS) or castration plus enzalutamide (ENZA) treatment were selected for d...
Source: Clinical Prostate Cancer - July 4, 2021 Category: Cancer & Oncology Authors: Lennart J van Winden Mirthe Lanfermeijer Annemieke C Heijboer Olaf van Tellingen Andries M Bergman Henk G van der Poel Niels Jonker Huub H van Rossum Source Type: research